open access

Vol 14, No 2 (2018)
Case report
Published online: 2018-04-26
Get Citation

The use of vismodegib in the treatment of basal cell carcinoma based on case reports

Monika Dudzisz-Sledz, Hanna Koseła-Paterczyk, Katarzyna Kozak, Paweł Rogala, Tomasz Świtaj, Sławomir Falkowski, Piotr Rutkowski
DOI: 10.5603/OCP.2018.0009
·
Oncol Clin Pract 2018;14(2):104-109.

open access

Vol 14, No 2 (2018)
CASE REPORT
Published online: 2018-04-26

Abstract

Basal cell carcinoma (BCC) is the most common skin cancer, usually located on the skin of the face and neck. Locally advanced cancer is diagnosed by about 5–10% of patients, while the metastatic disease is diagnosed in 0.0028 to 0.55% of cases. The primary treatment of locally advanced disease is radical surgery, and in non-operative cases — radiotherapy. For patients not eligible for local therapy and those with metastatic disease, systemic therapies, including hedgehog inhibitor — vismodegib — is used. In the Department of Melanoma and Soft Tissue and Bone Sarcomas, Maria Sklodowska-Curie Institute — Oncology Center several patients with BCC, not eligible for local therapy, are currently systemically treated. Vismodegib is registered for the use in adults with symptomatic metastatic basal cell carcinoma or locally advanced basal cell carcinoma that does not meet the criteria for surgical treatment or radiotherapy. In this paper, we present and discuss a case of BCC cancer in a metastatic setting and a case of a patient being treated for locally advanced disease not eligible for surgery and radiotherapy. The cases presented here confirm that vismodegib treatment, currently available in the national drug access program, provides an objective response, improvement in quality of life, and probably extension of survival.

Abstract

Basal cell carcinoma (BCC) is the most common skin cancer, usually located on the skin of the face and neck. Locally advanced cancer is diagnosed by about 5–10% of patients, while the metastatic disease is diagnosed in 0.0028 to 0.55% of cases. The primary treatment of locally advanced disease is radical surgery, and in non-operative cases — radiotherapy. For patients not eligible for local therapy and those with metastatic disease, systemic therapies, including hedgehog inhibitor — vismodegib — is used. In the Department of Melanoma and Soft Tissue and Bone Sarcomas, Maria Sklodowska-Curie Institute — Oncology Center several patients with BCC, not eligible for local therapy, are currently systemically treated. Vismodegib is registered for the use in adults with symptomatic metastatic basal cell carcinoma or locally advanced basal cell carcinoma that does not meet the criteria for surgical treatment or radiotherapy. In this paper, we present and discuss a case of BCC cancer in a metastatic setting and a case of a patient being treated for locally advanced disease not eligible for surgery and radiotherapy. The cases presented here confirm that vismodegib treatment, currently available in the national drug access program, provides an objective response, improvement in quality of life, and probably extension of survival.

Get Citation

Keywords

basal cell carcinoma, hedgehog pathway, vismodegib

About this article
Title

The use of vismodegib in the treatment of basal cell carcinoma based on case reports

Journal

Oncology in Clinical Practice

Issue

Vol 14, No 2 (2018)

Article type

Case report

Pages

104-109

Published online

2018-04-26

DOI

10.5603/OCP.2018.0009

Bibliographic record

Oncol Clin Pract 2018;14(2):104-109.

Keywords

basal cell carcinoma
hedgehog pathway
vismodegib

Authors

Monika Dudzisz-Sledz
Hanna Koseła-Paterczyk
Katarzyna Kozak
Paweł Rogala
Tomasz Świtaj
Sławomir Falkowski
Piotr Rutkowski

References (23)
  1. Charakterystyka produktu leczniczego Erivedge (wismodegib).
  2. Łasińska IM, Kocur J, Bajon T, et al. Vismodegib — a chance for improvement of quality of life in patients with locally advanced basal cell carcinoma — case report. Oncol Clin Pract. 2016; 12: 25–28.
  3. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012; 366(23): 2171–2179.
  4. Sekulic A, Migden MR, Basset-Seguin N, et al. Long term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): Final update (30 months) of pivotal ERIVANCE BCC study. J Clin Oncol. 2014; 32(suppl): 9013.
  5. Hansson J, Hauschild A, Kunstfeld R. Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts). J Clin Oncol. 2016; 34(suppl; abstr 9532).
  6. Kahana A, Worden FP, Elner VM. Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma. JAMA Ophthalmol. 2013; 131(10): 1364–1366.
  7. Edwards BJ, Raisch DW, Saraykar SS, et al. Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project. Drugs R D. 2017; 17(1): 211–218.
  8. Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005; 353(21): 2262–2269.
  9. Cirrone F, Harris CS. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma. Clin Ther. 2012; 34(10): 2039–2050.
  10. Dréno B, Kunstfeld R, Grob JJ i in. Vismodegib, a hedgehog pathway inhibitor, in advanced basal cell carcinoma: an interim analysis of the STEVIE Study in 500 patients. Abstract presented at the Society for Melanoma Research 2014 Zurych, Szwajcaria, 13–16 listopada 2014.
  11. Cowey CL. Targeted therapy for advanced Basal-cell carcinoma: vismodegib and beyond. Dermatol Ther (Heidelb). 2013; 3(1): 17–31.
  12. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009; 361(12): 1164–1172.
  13. Danhof R, Lewis K, Brown M. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin. Am J Clin Dermatol. 2017 [Epub ahead of print].
  14. Lyons TG, O'Kane GM, Kelly CM. Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma. Expert Opin Drug Saf. 2014; 13(8): 1125–1132.
  15. Amin SH, Motamedi KK, Ochsner MC, et al. Mechanisms and efficacy of vismodegib in the treatment of basal cell carcinoma. Discov Med. 2013; 16(89): 229–232.
  16. Rudin CM. Vismodegib. Clin Cancer Res. 2012; 18(12): 3218–3222.
  17. Dummer R, Guminski A, Gutzmer R, et al. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016; 75(1): 113–125.e5.
  18. Tan CZ, Rieger KE, Sarin KY. Basosquamous Carcinoma: Controversy, Advances, and Future Directions. Dermatol Surg. 2017; 43(1): 23–31.
  19. Chang AL, Arron ST, Migden MR, et al. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. Orphanet J Rare Dis. 2016; 11(1): 120.
  20. Basset-Séguin N, Hauschild A, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017; 86: 334–348.
  21. Basset-Seguin N, Hauschild A, Grob JJ, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015; 16(6): 729–736.
  22. Rogala P, Falkowski S. Wismodegib. Onkol Prakt Klin. 2014; 7: 1734–3542.
  23. Sekulic A, Migden MR, Basset-Seguin N, et al. ERIVANCE BCC Investigators. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017; 17(1): 332.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl